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Abstract
Background: More deaths occur in African women from invasive cervical cancer (ICC) than from any other
malignancy. ICC is caused by infection with oncogenic types of human papillomavirus (HPV). Co-infection with the
human immunodeficiency virus (HIV) accelerates the natural history of ICC, and may influence the HPV type
distribution. Because HPV vaccines are available, this malignancy is theoretically preventable, but the vaccines are
largely type-specific in protection against infection. Data on specific HPV types causing ICC in African women is
limited, and many studies utilized swab samples rather than actual cancer tissue. A previous study using archived,
ICC tissue from women in Botswana identified an unusual HPV type distribution. A similar study was therefore
performed in a second sub-Saharan country to provide additional information on the HPV type distribution in ICC.
Methods: Archived, formalin-fixed, paraffin-embedded ICCs were acquired from women in the United States,
Kenya, or Botswana. DNA was extracted and HPV genotyping performed by Roche Linear Array. HIV sequences
were identified in ICCs by PCR.
Results: HPV types 16 or 18 (HPV 16/18) were identified in 93.5 % of HPV-positive ICCs from the U.S., 93.8 % from
Kenya, and 61.8 % from Botswana (p < 0.0001). Non-HPV 16/18 types were detected in 10.9 % of HPV-positive
cancers from the U.S., 17.2 % from Kenya, and 47.8 % from Botswana (p < 0.0001). HIV was detected in 2.2, 31.5, and
32.4 % from ICCs from the U.S., Kenya, or Botswana, respectively (p = 0.0002). The distribution of HPV types was not
significantly different between HIVinfected or HIV-uninfected women. The percentages of ICCs theoretically covered
by the bivalent/quadrivalent HPV vaccines were 93.5, 93.9, and 61.8 % from the U.S., Kenya and Botswana,
respectively, and increased to 100, 98, and 77.8 % for the nanovalent vaccine.
Conclusions: HPV 16/18 caused most ICCs from the U.S. and western Kenya. Fewer ICCs contained HPV 16/18 in
Botswana. HIV co-infection did not influence the HPV type distribution in ICCs from African women from the two
countries. Available HPV vaccines should provide protection against most ICCs in the U.S. and Kenya. The recently
developed nanovalent vaccine may be more suitable for countries where non-HPV 16/18 types are frequently
detected in ICC.
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Background
An estimated 528,000 cases of invasive cervical cancer
(ICC) occurred worldwide in 2012 [1]. More deaths
occur in African women from cancer of the cervix than
from any other malignancy. The highest incidence rates
of ICC occur in Eastern and Southern Africa, with age
standardized rates (ASR) of 42.7 and 31.5 per 100,000
women, respectively [1].
Many obstacles exist for sub-Saharan countries in the
fight against cervical cancer, where this malignancy is di-
agnosed most often at ages 35 to 45 years, claiming the
lives of women when they may be raising children and
contributing to the economy of their communities [2]. All
but the least progressed stages of cervical cancer have high
case-fatality rates in this region of the world (estimated to
be greater than 50 %) due to poor access to effective treat-
ment modalities. Women with advanced cases have 2-year
survival rates of less than 20 % [3], and the average life-
years lost due to cervical cancer is greater than 18 [4]. Ef-
fective screening programs utilizing cervical cytology have
decreased the number of cases of ICC in developed na-
tions. However, screening is rarely performed in sub-
Saharan Africa, where more than 50 % of global cervical
cancer deaths occur.
Infection with oncogenic human papillomaviruses
(HPV) is the cause of ICC [5]. Cervical cancer can be
prevented by vaccination against HPV infection, but the
distribution of HPV types in invasive cancers has not
been fully characterized, especially in women infected
with the human immunodeficiency virus (HIV) [6].
As sub-Saharan African countries consider implement-
ing HPV vaccination, it is important to understand the
range of HPV types responsible for ICC cases in a country.
Surveillance and better understanding of local epidemi-
ology must be encouraged before selecting the HPV vac-
cine of choice for a specific country. The object of the
study was therefore to compare HPV typing data from a
previously published study of ICC cases in the United
States and Botswana [7] to additional cases identified in a
second sub-Saharan country, Kenya, and to determine the
HPV type distribution in invasive cervical cancers from
HIV-infected women living in these countries.
Methods
Human subject approval
Approval for the study was granted by the Institu-
tional Review Board at Indiana University School of
Medicine, University of Pennsylvania, the Botswana
Ministry of Health, Gaborone, Botswana, and by the
Institutional Research and Ethics Committee at Moi
University Teaching and Referral Hospital. All speci-
mens were de-identified prior to transport to the
HPV Laboratory.
Study specimens
Acquisition of archived, paraffin-embedded blocks of
formalin-fixed cervical cancer specimens from women
residing in Indianapolis, Indiana (U.S.) and from Botswana
was previously described [7]. Case selection was done by
working backwards in time among archived paraffin
blocks. All ICC specimens from the U.S. were obtained
from the Department of Pathology at Indiana University
School of Medicine.
Additional ICC specimens, obtained from 2010 to
2013 were identified at the Moi University Teaching and
Referral Hospital in Eldoret, Kenya. Section (5 μm) from
paraffin-embedded specimens were cut using a new
blade for each block. The first and last sections were
stained with hematoxylin and eosin for verification of
ICC. Specimens without invasive cancer tissue were
eliminated from the study.
The remainder of each block was transported to Indi-
ana University School of Medicine (Indianapolis), where
tissues were re-embedded due to apparent dehydration
of paraffin. Additional sections were prepared, and the
first and last sections were stained with hematoxylin and
eosin to verify the presence of ICC, Those without inva-
sive cancer tissue were eliminated from the study. For
specimens containing cancer tissue representing less
than an estimated 5 % of the total specimen, macro-
dissection was performed by identifying cancerous tissue
using a light microscope, marking the areas cancer tissue
on the undersurface of the slide, and removing this tis-
sue with a sterile scalpel.
HPV detection and typing
Thin-section polymerase chain reaction (PCR) of speci-
mens from Kenyan women was performed exactly as de-
scribed in a prior report of ICC cases from women living
in Botswana and the U.S. [7]. Briefly, four to six paraffin-
embedded tissue sections were scraped from slides pre-
pared from each block using a sterile blade. DNA extrac-
tion was then performed as previously described [7].
HPV detection and genotyping was performed using the
Linear Array HPV Genotyping Test (Roche, Indianapolis,
Indiana) as described [8]. The GH20/PC04 human β-
globin target was co-amplified to determine specimen ad-
equacy. For specimens positive for β-globin but negative
for HPV, DNA was extracted a second time from add-
itional sections. If the specimen was negative for β-globin
a second time, it was excluded in the analysis. If the speci-
men was positive for β-globin but negative for HPV a sec-
ond time, it was considered to be HPV-negative.
Detection of HIV
Sera were not available from women, as this study used
archived ICC specimens. In addition, medical records
were not available for most subjects. Therefore, HIV was
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detected by thin-section PCR using DNA extracted from
paraffin-embedded cervical cancer specimens as previ-
ously described [7]. Briefly, DNA extracted from paraffin
blocks was used to amplify a 142 base pair segment of the
HIV-1 gag gene (nucleotides 1360-1507) using primers
modified from An, SF et al [9]. Primer sequences were
SK145-M (5’-GGG ACA TCA AGC CAT GCA AAT-3’)
and SK431-M (5’-TGC TAT GTC AGT TCC CCT TGG
TTC TCT-3’). A plasmid containing the complete gag and
pol genes (pMDLg/pRRE) was used as a positive control
(provided by Kenneth Cornetta, Indiana University School
of Medicine, Indianapolis, IN). For PCR, 200 ng DNA
template was mixed with 25 μL of Master Mix FastStart
kit (Roche), 3 μM downstream and upstream primers, and
distilled water for a total volume of 50 μL. Reactions were
subjected to 1 cycle at 94 °C for 9 min, then 40 cycles at
94 °C for 30 s (denaturation), 55 °C for 30 s (annealing),
72 °C for 30 s (extension), followed by 1 cycle at 72 °C for
7 min (final extension) in a Mastercycler ProS (Eppendorf,
Hamburg, Germany).
HIV PCR products were analyzed on 1.8 % agarose gels.
To confirm the amplification of desired products, two re-
actions from cancers with an amplicon of expected size
were extracted from gels using the QIAquick Gel Extrac-
tion Kit (Qiagen) and sequenced bi-directionally. Hom-
ology of the sequenced samples with known HIV gag gene
sequences was verified using the Basic Local Sequencing
Alignment Search Tool (BLAST) search (NCBI).
Statistical analysis
This was a comparative study, not a clinic trial, as speci-
mens were archived. Adequacy of extracted DNA was
based on β-globin-positivity among ICC specimens. ICC
specimens positive for the β-globin human control gene
in the Roche Linear Array Assay were included in the ana-
lysis of HPV types. HPV type-specific prevalence (onco-
genic, or “high-risk” (HR types) and non-oncogenic, or
“low-risk (LR) types) was compared among β-globin-
positive ICCs from the three countries, and between spec-
imens that were from HIV-infected or HIV-uninfected
women from Kenya or Botswana. In addition, HPV types
were divided by their respective classification into Alpha 9
(A9 or HPV 16-related) and Alpha 7 (A7 or HPV 18-
related). The A9 types included HPV 16, 31, 33, 35, 52,
and 58, and A7 types included HPV 18, 39, 45, 59, and 68.
Prevalence of A9 and A7 types between countries were
compared using Fisher’s exact tests or Chi-square tests.
Analyses were performed using SAS (Version 9.3, SAS In-
stitute Inc., Cary, NC).
Results
Study specimens
Paraffin-embedded tissue blocks were previously ob-
tained from 51 women from the U.S. [7] (Table 1). All
51 specimens from the U.S. met criteria for tissue ad-
equacy based on the amount of epithelium present.
From Botswana, paraffin-embedded tissue blocks were
previously obtained from 214 women; 182 (85.0 %) met
adequacy criteria [7]. From Kenya, paraffin-embedded
tissue blocks were obtained from 210 women; 187
(89.0 %) met adequacy criteria. Fewer specimens from
Botswana or Kenya contained a sufficient amount of epi-
thelium compared to specimens from the U.S.; this dif-
ference was significant (p = 0.01).
HPV detection and HPV types in ICC specimens
Amplifiable DNA, as determined by amplification of
the human ß-globin target, was extracted from 50 of
51 (98.0 %) adequate specimens from the U.S., 171 of
182 (94.0 %) from Botswana, and 178 of 187 (95.2 %)
from Kenya (p = 0.49) (Table 1). HPV DNA of any
type was identified in 46 of 50 (92.0 %) U.S. speci-
mens with amplifiable DNA, 136 of 171 (79.5 %)
specimens from Botswana, and 146 of 178 (82.0 %)
Kenyan specimens (p = 0.128) (Table 1).
HR-HPV types were detected in 46 of 46 (100 %)
HPV-positive specimens from the U.S., 130 of 136
(95.6 %) from Botswana, and 145 of 146 (99.3 %) from
Kenya (p = 0.085) (Table 2). LR-HPV types were detected
in 0 of 46 (0.0 %) of HPV-positive specimens from the
U.S., 12 of 136 (8.8 %) from Botswana, and 3 of 146
(2.1 %) from Kenya (p = 0.007) (Table 2).
HPV 16 was the most frequently detected type in ICC
specimens from all three countries, detected in 40 of 46
(87.0 %) HPV-positive specimens from the U.S., 58 of
136 (42.7 %) from Botswana, and 118 of 146 (80.8 %)
from Kenya (P < 0.001) (Table 2). Next in frequency was
HPV 18, detected in 4 of 46 (8.7 %) HPV-positive speci-
mens from the U.S., 32 of 136 (23.5 %) from Botswana,
and 28 of 146 (19.2 %) from Kenya (p = 0.089) (Table 2).
Together, HPV types 16 and/or 18 were identified in 43
of 46 (93.5 %) HPV-positive specimens from the U.S., 84
of 136 (61.8 %) from Botswana, and 137 of 146 (93.8 %)
from Kenya (p < 0.0001) (not shown). Other HPV types
detected in ICC specimens are shown in Table 2.
Types other than HPV 16 and 18 (non-HPV 16/18
types) were detected in 5 of 46 (10.9 %) HPV-positive
specimens from the U.S., 65 of 136 (47.8 %) from
Botswana, and 25 of 146 (17.1 %) from Kenya (p < 0.001)
(Table 3). Non-HPV 16/18 HR types were detected in 5
of 46 (10.9 %) HPV-positive specimens from the U.S., 56
of 136 (41.2 %) from Botswana, and 22 of 146 (15.1 %)
from Kenya (p < 0.001) (Table 3).
A9 HPV types were detected in 41 of 46 (89.1 %)
HPV-positive specimens from the U.S., 79 of 136
(58.1 %) from Botswana, and 120 of 146 (82.2 %) from
Kenya (p < 0.001) (Table 3). Non-HPV 16 A9 types
(HPV 31, 33, 35, 52, and 58) were detected in 2 of 46
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(4.4 %) HPV-positive specimens from the U.S., 26 of 136
(19.1 %) from Botswana, and 7 of 146 (4.8 %) from
Kenya (p = 0.002) (Table 3).
A7 HPV types were detected in 7 of 46 (15.2 %) HPV-
positive specimens from the U.S., 49 of 136 (36.0 %) from
Botswana, and 40 of 146 (27.4 %) from Kenya (p = 0.022)
(Table 3). Non-HPV 18 A7 types (39, 45, 59, and 68) were
detected in 3 of 46 (6.5 %) HPV-positive specimens from
the U.S., 18 of 136 (13.2 %) from Botswana, and 12 of 146
(8.2 %) from Kenya (p = 0.259) (Table 3).
HIV detection and HPV type distribution in ICC specimens
By thin-section PCR, HIV sequences were detected in 2
of 50 (4.0 %) β-globin-positive specimens from the U.S.,
54 of 171 (31.6 %) from Botswana, and 55 of 178
(30.9 %) from Kenya (p = 0.0003). Looking at only those
specimens in which an HPV type was detected, HIV
sequences were detected by thin-section PCR in 1 of 46
(2.2 %) specimens from the U.S., 44 of 136 (32.4 %) from
Botswana, and 46 of 146 (31.5 %) from Kenya (p =
0.0002). As we had previously done for ICCs from
women in Botswana, an analysis was performed on ICCs
from Kenyan women in which an HPV type was de-
tected to determine if there were differences between
the HPV types in cases from HIV-infected women and
HIV-uninfected women. No differences in oncogenic
HPV types or groups of oncogenic HPV types were
found between ICC cases from HIV-infected or HIV-
uninfected Kenyan women (Additional file 1). This was
in contrast to ICCs from women living in Botswana, as
we previously reported, in which HPV 31 was detected
in 1 of 92 (1.1 %) ICCs from HIV-uninfected women
and 4 of 44 (9.1 %) ICCs from HIV-infected women.
Distribution of single HPV type vs. multiple HPV type
infections in ICC specimens
For all three countries combined, a single HPV type was
identified in 279 of 328 (85.1 %) ICC specimens that
contained any HPV type. There was no significant differ-
ence in the percentage of ICC specimens containing
more than a single HPV type between the three coun-
tries (data not shown). In addition, because HIV infec-
tion has been associated with detection of multiple HPV
types in clinical specimens in some studies, an analysis
was performed to determine if detection of multiple
HPV types was more common in cancers from HIV-
infected women compared to HIV-uninfected women.
In ICC specimens from the U.S., Botswana, and Kenya,
or the three countries combined, there was no signifi-
cant association between HIV status and the detection of
multiple HPV types (data not shown).
Theoretical protection against ICC afforded by HPV
vaccines
Three HPV vaccines are currently available in the United
States: the bivalent vaccine (Cervarix, GSK), the qu-
adrivalent vaccine (Gardasil, Merck), and a recently ap-
proved nine-valent vaccine (Gardasil 9, Merck). All
three provide excellent protection against HPV 16
and 18. The bivalent and quadrivalent vaccines may
each provide a degree of “cross protection” against
non-vaccine HR-HPV types, but this is likely to be
weak and short-lived compared to efficacy against the
oncogenic types actually represented in the vaccines
[10]. In contrast, the new nine-valent vaccine provides
a high degree of specific protection against infection
and disease caused by HR-HPV types 31, 33, 45, 52,
and 58, in addition to protection against HPV 16 and
HPV 18 [11].
Theoretical vaccine coverage by the currently available
HPV vaccines were calculated based on HPV types iden-
tified in the ICCs from the three countries (Table 4).
The bivalent and quadrivalent vaccines were assumed to
be 100 % protective against HPV types 16 and 18. This
analysis showed that for the U.S. (Indiana) and Kenya
(western Kenya), the bivalent and quadrivalent vaccines
should protect against a high percentage of ICC cases
(Table 4). In contrast, due to the number of non-HPV
16/18 types identified in ICCs from Botswana, the bi-
valent and quadrivalent vaccines may provide less pro-
tection in that country (Table 4). The percentages of
ICCs theoretically covered by the quadrivalent vaccine
were 93.5, 61.8, and 93.9 %. The nine-valent vaccine
would theoretically provide a higher degree of protection
against ICC among women living in any of the three
countries, but especially for women living in Botswana
(Table 4). The percentages of ICCs theoretically covered
by the nine-valent vaccine were 100, 77.8, and 98.0 % in
ICCs from the U.S., Botswana, and Kenya, respectively.
Table 1 Characteristics of invasive cervical cancers from the U.S., Botswana, and Kenya
Specimen characteristics U.S. Botswana Kenya p-value
Specimens obtained 51 214 210
Number of specimens with sufficient epitheliuma 51 (100 %) 182 (85.0 %) 187 (89.0 %) 0.01
β-globin-positive (of all specimens with sufficient epithelium) 50 (98.0 %) 171 (94.0 %) 178 (95.2 %) 0.491
HPV-positive (of β-globin-positive specimens) 46 (92 %) 136 (79.5 %) 146 (82.0 %) 0.128
aSee text (Methods) for explanation
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Discussion
It is important to understand differences in the HPV
types causing ICC in different regions of the world, and
differences in the HPV types causing ICC between
women who are infected or not infected with HIV. This
information is paramount in the fight against cervical
cancer, especially in the era of safe and effective vaccines
against HPV. It is entirely possible that HPV type distri-
butions could differ in ICC cases between different
countries in a large continent such as Africa. In addition,
Table 2 HPV types in HPV-positive invasive cervical cancers from the U.S., Botswana, and Kenya
HPV type U.S., N = 46 Botswana, N = 136 Kenya, N = 146 p-value
High-risk (HR) type distribution
HR-HPV 46 (100 %) 130 (95.6 %) 145 (99.3 %) 0.085
HPV 16 40 (87.0 %) 58 (42.7 %) 118 (80.8 %) <0.001
HPV 18 4 (8.7 %) 32 (23.5 %) 28 (19.2 %) 0.089
HPV 26 0 5 (3.7 %) 0 0.033
HPV 31 1 (2.2 %) 5 (3.7 %) 2 (1.4 %) 0.430
HPV 33 1 (2.2 %) 7 (5.2 %) 2 (1.4 %) 0.143
HPV 35 0 8 (5.9 %) 1 (0.7 %) 0.021
HPV 39 0 6 (4.4 %) 1 (0.7 %) 0.085
HPV 45 3 (6.5 %) 12 (8.8 %) 9 (6.2 %) 0.676
HPV 51 0 3 (2.2 %) 0 0.123
HPV 52 0 4 (2.9 %) 0 0.081
HPV 53 0 1 (0.7 %) 0 0.555
HPV 56 0 0 0 -
HPV 58 0 2 (1.5 %) 2 (1.4 %) 1.000
HPV 59 0 2 (1.5 %) 2 (1.4 %) 1.000
HPV 66 0 4 (2.9 %) 0 0.081
HPV 67 0 1 (0.7 %) 0 0.555
HPV 68 0 2 (1.5 %) 0 0.432
HPV 69 0 1 (0.7 %) 0 0.555
HPV 70 0 0 0 -
HPV 73 0 0 1 (0.7 %) 1.000
HPV 82 0 2 (1.5 %) 2 (1.4 %) 1.000
HPV IS39 0 0 0 -
Low-risk (LR) type distribution
LR-HPV 0 12 (8.8 %) 3 (2.1 %) 0.007
HPV 6 0 1 (0.7 %) 0 0.555
HPV 11 0 1 (0.7 %) 3 (2.1 %) 0.795
HPV 40 0 1 (0.7 %) 0 0.555
HPV 42 0 0 0 -
HPV 54 0 0 0 -
HPV 55 0 1 (0.7 %) 0 0.555
HPV 61 0 0 0 -
HPV 62 0 0 0 -
HPV 71 0 0 0 -
HPV 72 0 0 0 -
HPV 81 0 1 (0.7 %) 0 0.555
HPV 83 0 2 (1.5 %) 0 0.432
HPV 84 0 6 (4.4 %) 0 0.017
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because there are several available methods for both col-
lection of cancer cells/tissue and for HPV analysis, com-
paring studies can be difficult.
More country-specific data is needed before conclusions
can be drawn. Two analyses of studies performed in
African women suggested that HPV 16 was present in ap-
proximately half of ICCs, the lowest prevalence among
the major regions of the world [12]. Our own previous
study of ICCs obtained from women in Botswana (and in-
cluded in this study) utilized thin section PCR of actual
ICC tissue. DNA was directly extracted from sections of
ICC and analyzed using the Roche Linear Array assay.
The analysis demonstrated a prevalence of 42.7 % for
HPV 16, compared to 87 % of ICCs from the U.S. [7].
We wanted to expand the analysis, using identical
methods of tissue collection and HPV typing to a second
sub-Saharan country, Kenya. The current study was
therefore designed to compare and contrast HPV types
causing ICC in the U.S., Botswana, and Kenya. Using a
direct approach known as thin-section PCR, we found
that the distribution of HPV types in ICC specimens
from western Kenyan women was similar to that in can-
cers from the U.S. No statistically significant differences
were found for individual HPV types or for groups of
types. HPV 16 was the most frequently detected type in
ICCs from women living in the U.S. (87.0 %) and from
women living in Kenya (82.0 %). Together, HPV types 16
or 18 were detected in approximately 94 % of ICC speci-
mens from both the U.S. and Kenya.
In contrast, the differences between HPV types in ICCs
from women living in Kenya and Botswana are striking
and likely not exclusively related to HIV infection preva-
lence. Fewer ICCs from women living in Botswana con-
tained HPV 16. More non-HPV 16/18 oncogenic types
were identified in ICCs from women living in Botswana
compared to those from the U.S. or Kenya.
Other groups have also examined ICC cases from sub-
Saharan African women, but in each case, different
methods were utilized in both sampling and in HPV de-
tection, compared to our study and to each other. Sev-
eral other studies have included data on HIV status as
well, but utilized serological HIV testing, as such in-
formation was available. For example, De Vuyst et al.,
conducted a study of Kenyan women with ICC [13].
Fifty-one HIV-infected women were matched by age to
153 HIV-uninfected women. Exfoliated cervical cells
from women with ICC were collected and tested for
HPV DNA using the PCR-based SPF10-INNO-LiPA sys-
tem. The actual tumor was apparently not sampled in
this study. Multiple-type infections were more frequent
in HIV-infected (37.2 %) than in HIV-uninfected
(13.7 %) women, but the overall distribution of HPV
types was similar. HPV16 was detected in 41.2 % versus
43.8 % and HPV16 and/or 18 in 64.7 % versus 60.1 % of
HIV-infected versus HIV-uninfected women, respectively.
Another study from this group was performed to de-
termine associations of HPV infection and cervical
intraepithelial neoplasia (CIN) among 498 HIV-infected
Kenyan women who underwent HPV PCR-based testing,
cytology, and cervical biopsy [14]. Overall, 68.7 % of
women were HPV-positive, 52.6 % with HR-HPV, and
40.2 % had multiple type infections. The most frequent
types in 113 CIN2/3 cases were HPV 16 (26.5 %), HPV 35
(19.5 %), and HPV 58 (12.4 %). CD4 count was negatively
associated with detection of HR-HPV (P < 0.001) and
CIN2/3 among women not receiving anti-retroviral treat-
ment (P = 0.013). The authors concluded that the burden
of HR-HPV and CIN2/3 was high in HIV-infected Kenyan
women and was related to immunosuppression level. A
Table 3 Distribution of groups of HPV types, Alpha 9 and Alpha 7 types in HPV-positive ICC specimens
U.S. (N = 46) Botswana (N = 136) Kenya (N = 146) p-value
All non-HPV 16/18 types 5 (10.9 %) 65 (47.8 %) 25 (17.1 %) <0.001
Non-HPV 16/18 HR types 5 (10.9 %) 56 (41.2 %) 22 (15.1 %) < 0.001
A9 Typesa 41 (89.1 %) 79 (58.1 %) 120 (82.2 %) < 0.001
HPV 16 40 (87.0 %) 58 (42.7 %) 118 (80.8 %) < 0.001
Non-16 A9 Types 2 (4.4 %) 26 (19.1 %) 7 (4.8 %) 0.002
A7 Typesb 7 (15.2 %) 49 (36.0 %) 40 (27.4 %) 0.022
HPV 18 4 (8.7 %) 32 (23.5 %) 28 (19.2 %) 0.089
Non-18 A7 Types 3 (6.5 %) 18 (13.2 %) 12 (8.2 %) 0.259
aA9 types = HPV types 16, 31, 33, 35, 52, and 58
bA7 types = HPV types 18, 39, 45, 59, and 68
Table 4 Theoretical protection of HPV vaccines against invasive
cervical cancer in the U.S., Botswana, or Kenya, based on data in
the current analysis, assuming 100 % vaccine efficacy against
oncogenic HPV types represented in the vaccines. The bivalent
vaccine is represented by “2X”, the quadrivalent vaccine by “4X”,
and the nine-valent vaccine by “9X”
U.S. Botswana Kenya
2X/4X vaccine 93.5 % 61.8 % 93.9 %
9X vaccine 100 % 77.8 % 98 %
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third study from that group examined frozen tissue biop-
sies from women with ICC in Kenya and South Africa
[15]. One hundred and six HIV-infected and 129 HIV-
uninfected women with ICC were included. A fragment
from the biopsy was tested for HPV DNA using GP5+/6
+ -PCR assay Multiple HPV types were identified in
21.6 % of ICCs from HIV-infected women compared
3.3 % in HIV-uninfected women. HPV16 and/or 18 preva-
lence combined was similar in ICCS from HIV-infected
(66.7 %) and HIV-uninfected women (69.1 %) No signifi-
cant difference was found for other HPV types between
the two groups. The authors concluded that current
prophylactic HPV vaccines against HPV 16 and 18 may
prevent similar proportions of cervical cancers in HIV-
infected and HIV-uninfected Kenyan women.
A recent study by Maranga et al., examined HPV types
in cervical smears and carcinomas from HIV-infected and
HIV-uninfected Kenyan women [16]. Smear samples from
women were analyzed, and those from HIV-infected
women had a higher rate of detection of HR-HPV types
52, 58, 68, potential high risk 53/70, and low-risk 44/55
compared to HIV-uninfected women. HPV types 16/18
were detected in cells collected from ~46 % of HIV-
infected women and ~46 % of HIV-positive women. HPV
45 was more common in cells collected from HIV-
infected women. The authors concluded that HIV in-
fection may alter the spectrum of HPV types found in cer-
vical smears and in ICC.
HIV co-infection accelerates the natural history of cer-
vical cancer. For Kenya and Botswana, we did not know
the HIV status for the women. Using a thin-section PCR
devised by our group, HIV was identified in ~32 to 34 %
of ICC specimens from women living in Botswana or
Kenyan, compared to ~4 % of ICCs from women living
in Indiana. These numbers do not reflect the HIV preva-
lence of all women in these countries but illustrate the
higher incidence of ICC in HIV-infected women. More
studies of the thin-section PCR for HIV are needed to
validate this potentially useful assay. Based on studies by
other groups, we expected that ICCs from women who
were HIV-infected may have a different HPV type distribu-
tion that from ICCs from HIV-uninfected women in these
countries [17]. However, when ICC cases were stratified by
HIV status, no significant differences were found for any
HPV type or groups of types. The reason for this observa-
tion is not clear, and further study is needed.
The current study has implications for health policies
related to prevention of cervical cancer. This study indi-
cates that HPV types 16 and 18 are the primary types
causing ICC in Indiana, U.S., and in western Kenya.
However, our recent study in Botswana (and shown
again in this manuscript) showed a different HPV type
distribution. As indicated above, three HPV vaccines are
currently available: the bivalent vaccine, the quadrivalent
vaccine, and the nine-valent vaccine. All are expensive,
costing approximately $360 in the U.S. for the series of
three required doses. All three provide excellent protec-
tion against HPV 16 and 18. The nine-valent HPV
vaccine includes VLPs present in the quadrivalent
vaccine (HPV types 6, 11, 16, and 18) plus VLPs of five
additional HR-HPV types (31, 33, 45, 52, and 58) [11].
When global data is examined, the five additional HR-
HPV types in the nine-valent HPV vaccine account for
approximately 12 % of all cervical cancers [11]. Com-
bined with HPV 16 and HPV 18 estimates, the nine-
valent HPV vaccine has the potential to protect against
nine types responsible for greater than 90 % of cervical
cancers. The U.S. Food and Drug Administration (FDA)
recently approved the nine-valent vaccine for use. A
cost-benefit analysis would be required to determine if
the newer vaccine would be worth any additional cost,
in terms of life-years gained compared to the other avail-
able HPV vaccines.
How important would the nine-valent HPV vaccine be
in Botswana? Due to the large percentage of non-HPV
16/18 types identified in the ICC cases in Botswana, the
bivalent and quadrivalent vaccines would theoretically
provide less protection against ICC than it would for
women in Kenya or the U.S. The nine-valent vaccine
would theoretically provide a higher degree of protection
against ICC among women living in Botswana.
There are several limitations to this study. First, only
ICC cases from western Kenya were included and results
cannot be generalized to the entire country of Kenya.
Second, this study used paraffin-embedded cervical can-
cers, and as a result, the sensitivity for HPV detection
could be less than if fresh cancer tissues had been avail-
able. Because the current study used archived speci-
mens, fixation conditions could not be controlled and
may have contributed to differences between countries
in the frequencies of HPV detection [18]. Third, it is
possible that the techniques used to recover DNA and
detect/type HPV have differing capabilities for certain
HPV types, thus potentially underrepresenting non-HPV
16/18 HPV types. However, the Roche Linear Array is
the standard detection and typing method in epidemio-
logic studies of HPV, and in other studies has demon-
strated the capacity to detect numerous HPV types in
cervical cancers [19]. Fourth, only 85 to 89 % of the
samples from African women were analyzed due to in-
adequate epithelium histologically, and the inability to
identify HPV in roughly 20 % of the African specimens
could shift the results and conclusions, given the small
size of the study. Fifth, the proportion of HPV-negative
cancers in Botswana (among those with adequate beta-
globin DNA) is curious and could be related to differ-
ences in fixation and processing techniques as men-
tioned above. It is possible that HPV types in some of
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these ICCs are not detected in the Linear Array Assay.
Sixth, previous studies detected HPV 16 in ~70 to 80 %
of ICC cases, compared to >90 % in our study for the
ICCs from the U.S. and Kenya. While it is possible that
our methods overestimate HPV 16/18 prevalence in
ICCs, there is no evidence to support this. Most previ-
ous studies used cervical swabs rather than thin-section
PCR to capture tumor cells and to determine HPV types
in the cancers but this could lead to an overestimation
of the role of certain HPV types when compared to thin-
section PCR performed directly on ICCs. Lastly, the HIV
status of women in Kenya and Botswana was not known.
Therefore, an indirect method a thin-section PCR was
developed to determine the HIV status of these women.
The sensitivity and specificity of this novel method has
not yet been determined, but we verified the authenticity
of HIV sequences in two ICC specimens.
Conclusions
Continued efforts must be made to improve utilization
of the HPV vaccines, and with the help of the World
Health Organization and other agencies, and hopefully a
reduced price of the nine-valent HPV vaccine can be ne-
gotiated for countries in which non-HPV 16/18 types
are frequently identified in careful studies of ICC. For
now, every effort should be made to vaccinate young
girls and adolescent women with any of the currently
available HPV vaccines. This will help assure a cervical
cancer-free future for Kenya, Botswana, and other sub-
Saharan countries where cervical cancer screening is not
widely available.
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